A number of other research firms also recently issued reports on MYGN. ValuEngine raised Myriad Genetics from a hold rating to a buy rating in a research report on Friday, November 10th. Barclays reissued a hold rating and issued a $30.00 target price on shares of Myriad Genetics in a research report on Monday, January 8th. Zacks Investment Research downgraded Myriad Genetics from a strong-buy rating to a hold rating in a research report on Friday, December 15th. Deutsche Bank raised their target price on Myriad Genetics from $28.00 to $30.00 and gave the stock a hold rating in a research report on Wednesday, November 8th. Finally, Stephens set a $45.00 target price on Myriad Genetics and gave the stock a buy rating in a research report on Wednesday, January 3rd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $30.09.
Myriad Genetics (NASDAQ:MYGN) traded up $0.63 during trading hours on Tuesday, reaching $38.62. The company’s stock had a trading volume of 924,062 shares, compared to its average volume of 679,728. The company has a quick ratio of 2.06, a current ratio of 2.34 and a debt-to-equity ratio of 0.09. Myriad Genetics has a twelve month low of $15.15 and a twelve month high of $38.65. The stock has a market capitalization of $2,670.00, a P/E ratio of 26.09, a P/E/G ratio of 2.34 and a beta of 0.24.
Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.05. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The business had revenue of $190.20 million during the quarter, compared to the consensus estimate of $183.52 million. During the same period last year, the business posted $0.23 earnings per share. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. analysts forecast that Myriad Genetics will post 1.05 EPS for the current year.
In related news, VP Gary A. King sold 3,120 shares of Myriad Genetics stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $38.12, for a total transaction of $118,934.40. Following the completion of the sale, the vice president now owns 125,088 shares of the company’s stock, valued at $4,768,354.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Alexander Ford sold 3,031 shares of Myriad Genetics stock in a transaction on Monday, November 13th. The shares were sold at an average price of $31.64, for a total value of $95,900.84. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,410 shares of company stock valued at $1,163,524. 6.70% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the stock. GHP Investment Advisors Inc. boosted its stake in Myriad Genetics by 11.1% during the third quarter. GHP Investment Advisors Inc. now owns 48,710 shares of the company’s stock valued at $1,762,000 after buying an additional 4,853 shares during the period. Vanguard Group Inc. boosted its stake in Myriad Genetics by 0.9% during the second quarter. Vanguard Group Inc. now owns 6,307,738 shares of the company’s stock valued at $162,992,000 after buying an additional 56,708 shares during the period. PDT Partners LLC bought a new stake in Myriad Genetics during the second quarter valued at $8,481,000. Shell Asset Management Co. boosted its stake in Myriad Genetics by 34.3% during the third quarter. Shell Asset Management Co. now owns 54,867 shares of the company’s stock valued at $2,116,000 after buying an additional 14,021 shares during the period. Finally, Prudential Financial Inc. boosted its stake in Myriad Genetics by 3.9% during the third quarter. Prudential Financial Inc. now owns 131,073 shares of the company’s stock valued at $4,742,000 after buying an additional 4,900 shares during the period.
COPYRIGHT VIOLATION NOTICE: “BTIG Research Analysts Give Myriad Genetics (MYGN) a $41.00 Price Target” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://ledgergazette.com/2018/01/19/btig-research-analysts-give-myriad-genetics-mygn-a-41-00-price-target.html.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.